In addition, a systematic review of 311 clinical trials demonstrated that HAIC plus lenvatinib and PD-1 inhibitors effectively delayed disease progression, prolonged survival, and improved quality of life in HCC patients with portal vein tumor thrombus (35). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.